  Quantitative imaging can facilitate patient stratification in clinical trials. The hypoxia-activated prodrug evofosfamide recently failed a phase III trial in pancreatic cancer. However , the study did not attempt to select for patients with hypoxic tumors. We tested the ability of Two forms of evofosfamide were used: ( 1) labeled on the active moiety ( There was significant individual variation in None